Department of Laboratory Medicine of the Medical Clinic at the University Medical Center Knappschaftskrankenhaus Bochum, Ruhr University, Bochum, Germany.
Institute of Laboratory Medicine, Microbiology and Hygiene, Barmherzige Brüder Hospital, Regensburg, Germany.
J Allergy Clin Immunol. 2020 Jul;146(1):35-43. doi: 10.1016/j.jaci.2020.05.020. Epub 2020 May 29.
Severe acute respiratory syndrome coronavirus 2 infection and development of coronavirus disease 2019 presents a major health care challenge of global dimensions. Laboratory diagnostics of infected patients, and the assessment of immunity against severe acute respiratory syndrome coronavirus 2, presents a major cornerstone in handling the pandemic. Currently, there is an increase in demand for antibody testing and a large number of tests are already marketed or are in the late stage of development. However, the interpretation of test results depends on many variables and factors, including sensitivity, specificity, potential cross-reactivity and cross-protectivity, the diagnostic value of antibodies of different isotypes, and the use of antibody testing in identification of acutely ill patients or in epidemiological settings. In this article, the recently established COVID-19 Task Force of the German Society for Clinical Chemistry and Laboratory Medicine (DGKL) addresses these issues on the basis of currently available data sets in this rapidly moving field.
严重急性呼吸综合征冠状病毒 2 感染和 2019 年冠状病毒病的发生对全球医疗保健提出了重大挑战。对感染患者的实验室诊断以及对严重急性呼吸综合征冠状病毒 2 的免疫评估，是应对这一大流行病的主要基石。目前，对抗体检测的需求不断增加，大量检测已经上市或处于后期开发阶段。然而，检测结果的解释取决于许多变量和因素，包括敏感性、特异性、潜在的交叉反应和交叉保护作用、不同同种型抗体的诊断价值，以及在识别急性疾病患者或在流行病学环境中使用抗体检测。在这篇文章中，德国临床化学和实验室医学学会（DGKL）最近成立的 COVID-19 工作组根据这一快速发展领域中目前可用的数据集，解决了这些问题。
